Table 1.

Sociodemographical and Clinical Data of the Sample

		Controls (N = 100)	SCH (N = 188)	P Value
Sociodemographic
Age ($\tilde{\text{X}}$ ± SD)		42.6 ± 12.6	38.4 ± 8.7	.003
Sex (% men)		48	71.2	<.001
Years of education ($\tilde{\text{X}}$ ± SD)		15.5 ± 5.3	12 ±3.2	<.001
IQ ($\tilde{\text{X}}$ ± SD)		42 ± 9.1	35.6 ± 9.5	<.001
Number of cigarettes ($\tilde{\text{X}}$ ± SD)		6.4 ± 11.7	16.3 ± 14.5	<.001
Tobacco consumption (% SM/% FS/% NS)		28.3/13.1/58.6	66.8/5.2/28	<.001
Labor status (% active)		89.7	32.8	<.001
Clinical
% Deficit syndrome			34.7
Age at onset ($\tilde{\text{X}}$ ± SD)			23.4 ± 6.2
Duration of illness ($\tilde{\text{X}}$ ± SD)			14.6 ± 8.4
Age at first hospitalization ($\tilde{\text{X}}$ ± SD)			26.5 ± 7.6
Number of hospitalizations ($\tilde{\text{X}}$ ± SD)			3.5 ± 3.7
Stabilization (months) ($\tilde{\text{X}}$ ± SD)a			45.6 ± 45.4
Suicide attempts (%)			13.2
PANSS ($\tilde{\text{X}}$ ± SD)	Total		54.9 ± 15.7
	Positive		11.5 ± 4.4
	Negative		17.4 ± 7.7
	GS		26.3 ± 6.3
Pharmacological
Number of psychopharmacs ($\tilde{\text{X}}$ ± SD)			1.6 ± 0.8
Antipsychotics (% No/% FGA/% SGA)			2.1/17.6/80.3
Antidepressive (%)			10.4
BZD (%)			25.9

Note: $\tilde{\text{X}}$, media; SD, standard deviation; SCH, schizophrenia; SM, smokers; FS, former smokers; NS, nonsmokers; DF, deficitary; GS, general syndrome; FGA, first-generation antipsychotic; SGA, second generation antipsychotic; BZD, benzodiazepine; In bold, significant associations.

^aMinimum 3 months.